Kyverna Therapeutics (KYTX) Retained Earnings (2023 - 2026)

Kyverna Therapeutics (KYTX) has 4 years of Retained Earnings data on file, last reported at -$464.6 million in Q1 2026.

• Quarterly Retained Earnings fell 50.77% year-over-year to -$464.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$464.6 million (down 50.77% YoY) and the FY2025 annual result came in at -$424.8 million, down 61.21% from the prior year.
• Retained Earnings eased to -$464.6 million in Q1 2026, from -$424.8 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of -$1000.0 in Q1 2024 to a low of -$464.6 million in Q1 2026.
• A 4-year average of -$256.0 million and a median of -$285.8 million in 2024 frame the typical range for Retained Earnings.
• Annual changes were most pronounced in 2025 — Retained Earnings slumped 30815400.0% — and 2026, when it slumped 50.77%.
• Tracing KYTX's Retained Earnings over 4 years: stood at -$136.0 million in 2023, then sank by 93.7% to -$263.5 million in 2024, then tumbled by 61.21% to -$424.8 million in 2025, then declined by 9.36% to -$464.6 million in 2026.
• The last three Retained Earnings figures came in at -$464.6 million (Q1 2026), -$424.8 million (Q4 2025), and -$387.0 million (Q3 2025), per Business Quant data.